Spero Therapeutics (STU:2HA) Total Assets : €71.88 Mil (As of Mar. 2025)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics Total Assets?

Spero Therapeutics's Total Assets for the quarter that ended in Mar. 2025 was €71.88 Mil.

During the past 12 months, Spero Therapeutics's average Total Assets Growth Rate was -66.30% per year. During the past 3 years, the average Total Assets Growth Rate was 32.70% per year. During the past 5 years, the average Total Assets Growth Rate was 25.90% per year.

During the past 10 years, Spero Therapeutics's highest 3-Year average Total Assets Growth Rate was 109.00%. The lowest was -13.30%. And the median was 58.70%.

Total Assets is connected with ROA %. Spero Therapeutics's annualized ROA % for the quarter that ended in Mar. 2025 was -57.82%. Total Assets is also linked to Revenue through Asset Turnover. Spero Therapeutics's Asset Turnover for the quarter that ended in Mar. 2025 was 0.05.

Spero Therapeutics Total Assets Historical Data

The historical data trend for Spero Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics Total Assets Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Assets

Get a 7-Day Free Trial

126.14

151.40

117.81

167.25

105.57

Spero Therapeutics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Total Assets	Get a 7-Day Free Trial															154.29	139.24	121.78	105.57	71.88

Spero Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Spero Therapeutics's Total Assets for the fiscal year that ended in Dec. 2024 is calculated as

Total Assets	=	Total Equity (A: Dec. 2024 )	+	Total Liabilities (A: Dec. 2024 )
	=	44.047	+	61.521
	=	105.57

Spero Therapeutics's Total Assets for the quarter that ended in Mar. 2025 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2025 )	+	Total Liabilities (Q: Mar. 2025 )
	=	31.278	+	40.603
	=	71.88

Spero Therapeutics (STU:2HA) Total Assets Explanation

Total Assets is connected with ROA %.

Spero Therapeutics's annualized ROA % for the quarter that ended in Mar. 2025 is

ROA %	=	Net Income (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
	=	-51.304	/	( (105.569	+	71.881)	/ 2 )
	=	-51.304	/	88.725
	=	-57.82 %

Note: The Net Income data used here is four times the quarterly (Mar. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Spero Therapeutics's Asset Turnover for the quarter that ended in Mar. 2025 is

	Asset Turnover
=	Revenue (Q: Mar. 2025 )	/	( (Total Assets (Q: Dec. 2024 )	+	Total Assets (Q: Mar. 2025 ))	/ count )
=	4.728	/	( (105.569	+	71.881)	/ 2 )
=	4.728	/	88.725
=	0.05

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Spero Therapeutics Total Assets Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

SPRO:USA 2HA:Germany

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics Headlines

No Headlines